CBD for Inflammation: Evidence for Pain Relief and Its Limits

Editor’s Note: Our Masterclass series is supported by our readers. When you purchase through links on our site, we may earn an affiliate commission at no extra cost to you.

CBD is often marketed for inflammation and joint pain, but the evidence does not support promising reliable relief from a cream or gummy. Laboratory findings and early clinical studies are reasons to investigate CBD, not proof that a retail product controls inflammatory disease. Pain relief, reduced inflammation, and prevention of joint damage are different outcomes.

What Oral CBD Studies Show

In a 2023 randomized knee osteoarthritis trial, 86 participants received either oral CBD at 600 mg daily or placebo alongside continued paracetamol. CBD provided no additional analgesic benefit. The research dose is not a recommendation for self-treatment.

The CANOA trial published in December 2025 randomized 45 people with knee osteoarthritis to CBD-rich cannabis oil or placebo for 60 days. The oil supplied 45 mg of CBD per day. Pain improved in both groups, but the oil did not outperform placebo. That result illustrates why improvement after starting a product does not, by itself, demonstrate that the product caused the improvement.

The 2025 AHRQ chronic-pain review likewise found no improvement in pain or function with oral CBD alone compared with placebo. Some THC-containing products had small short-term benefits, largely in neuropathic pain research, alongside more adverse effects. Those findings cannot be transferred to CBD gummies or treated as evidence that CBD controls chronic inflammation.

Are CBD Topicals Different?

A small 2022 randomized crossover trial studied 18 people with thumb basal joint arthritis. Participants used a CBD-and-shea-butter preparation or shea butter alone for two weeks each, separated by a washout period. The CBD preparation improved reported pain and disability compared with the control, but grip strength, pinch strength, and range of motion were similar.

This is an encouraging short-term result for a particular preparation and condition. It does not establish that all CBD creams work, that they reach every painful joint, or that they prevent arthritis progression. It also does not establish effectiveness for post-workout recovery. Larger, longer studies are needed before making broad claims about topical CBD.

Product Choice Does Not Establish a Therapeutic Dose

No established retail CBD dose guarantees sustained anti-inflammatory benefit. The time a product takes to be absorbed is not the same as the duration of meaningful symptom relief. Claims that a gummy maintains therapeutic levels or delivers eight hours of inflammatory support require clinical evidence for that product.

Safety and a Practical Treatment Plan

The FDA warns that CBD can cause liver injury, interact with medicines, and cause drowsiness or digestive side effects. Its approved prescription use is for certain seizure disorders, not inflammation or arthritis. Oral research should not be used to assume that a topical preparation has the same exposure, benefits, or risks.

Persistent pain or swelling needs assessment of its cause. Ask a clinician what treatment addresses the underlying condition, whether a proposed CBD product could interact with current medicines, and what improvement would justify continuing it. Do not replace prescribed arthritis treatment with CBD on the basis of an anti-inflammatory marketing claim.

In the next article, we examine the evidence for Chapter 8: Mental Health & Anxiety.